True about zafirlukast is (DNB Dec, 2012)
|A||It inhibit lipooxygenase pathway|
|B||It decreases the frequency of asthma attacks as com- pared to glucocorticoids|
|C||It blocks LT receptor|
|D||It is effective in acute bronchial asthma|
|E||It can be administered orally|
Zafirlukast and montelukast are cysteinylleukotriene receptor antagonists. They cause modest improvementinha function and reduction in asthma symptoms and lessen the need for beta-agonist rescue herapy. These drugscan~ considered as alternatives to low-dose inhaled corticosteroids in patients with persistent asthma.
Zafirlukast is long acting and can be given twice to once daily orally. It is a modest bronchodilator that reduC!!
asthma morbidity, provides protection against exercise induced asthma and diminishes nocturnal symptoms.
These are less effective than corticosteroids.